- Journalists Assess Risks of Tick Bites, Wildfire Smoke, Rising Health Costs
- Jefferson Health sues Independence Blue Cross over nearly $100M in disputed payments
- 240 community hospital CEOs to know | 2026
- 4 behavioral health data breaches making headlines
- 17 recent hospital, health system president exits
- 5 federal behavioral health bills for leaders to watch
- HHS appeals decision vacating provisions of 2025 ACA marketplace rule
- Imagen Dental Partners adds Seattle practice
- Texas dental practice suffers data breach
- Health systems alter approaches to workforce housing
- ACA fallout hits for-profit health systems harder than expected
- 25 new behavioral health study findings to know
- Rural hospitals build scale to stay independent: Commonwealth Fund
- Lunch, low acuity and ‘family’: How ASCs beat the CRNA cost crunch
- HCA’s $1.2B ACA hit raises red flag for nonprofit health systems
- Where AI is delivering the biggest supply chain wins
- Northwell’s Lenox Hill Hospital Brain Tumor Center Gala raises $1.6M
- Florida dental office remains closed amid patient death investigation
- Lyon College dental school names inaugural medical director for pediatric program
- A massive month for ASC policy: 5 key updates
- 130+ DSO affiliations so far in 2026: State-by-state breakdown
- AHA releases SUD treatment toolkits
- 8 DSOs making headlines
- California unveils $109M for behavioral health supportive housing
- Idaho physician to pay $1.25M for Medicare, telemedicine fraud scheme
- Connecticut enacts sweeping CON reforms: 10 things to know
- The 1st physician specialty to top $600K
- 38% of teens use a substance by age 16: 5 study notes
- Why it’s time to ‘jettison’ Stark law
- Allina Health to open 620,000-square-foot surgery center
- Tenet Healthcare shrugs off ACA headwinds with sweeping Q2 outperformance, boosts 2026 guidance
- FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments
- Frequent Marijuana Use Linked To Higher Stress Hormone Levels
- What's behind Aetna's investments to build provider trust
- New university initiative offers screening, referrals for endometriosis
- Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
- HCA Healthcare's H1 ACA volume dropoffs 'almost one for one' shifted to uninsurance
- Novo escalates Lilly false advertising suit with planned bid to halt comparative ads
- Industry Voices—The new model for rural healthcare is already taking shape
- Amgen hands in data package in hopes of FDA hearing for Tavneos defense
- Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial
- Back Pain? Try Swimming, Study Says
- Ozempic Cuts Down Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
- Money Problems Might Make Your Brain Old Before Its Time, Study Suggests
- GSK’s first lung cancer approval, a new IPO path and more
- Merck stages expanded access to monthly HIV PrEP pill ahead of approval
- Black MS Patients Dying Younger Than White Ones, Study Finds
- Public Health Improvements Stall Amid Trump's DEI Crackdown
- Watch: GOP Senator Says Trump’s Tariffs Could Mean Safer Drugs — For a Price
- ‘The Child Is Terrified’: Doctors on the Front Lines of a Measles Comeback Speak Out
- To Afford Aging in Place, Older Adults Turn to ‘Golden Girls’ Housing
- Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey
- OpenAI makes Health in ChatGPT widely available, moving deeper into consumer health
- Many U.S. Schools Unprepared To Help Concussed Students Return To The Classroom
- Oral surgery platform buys back ownership stake from private equity firm
- Stamford Health opens EmPATH unit with follow-up care
- What will it take to truly fix anesthesia?
- 5 forces reshaping physician compensation in 2026
- Cardiologists’ pay averaged $575K in 2025, yet half feel underpaid: 10 stats to know
- New York unveils dashboard tracking mental health investments
- PDS Health-anchored retail pad in South Carolina sold for $3.7M
- 15 behavioral health services, facility closures | 2026
- Growth in a year the industry slowed: what Elevate Dental Partners is doing differently
- Philadelphia dentist whose patients were urged to get tested for HIV, hepatitis to reopen practice
- The unlicensed therapist 8 million kids are seeing
- Fierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPO
- New CMS data spotlight continued rise in No Surprises Act disputes
- Weekly Rundown: FDA names Dexcom as first TEMPO participant; Ardent Health tops 1M patient visits with ambient AI
- UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
- Nearly 1.6 Million Dozen Eggs Pulled From Shelves Over Salmonella Concerns
- Molina Healthcare plans more marketplace exits as ACA segment falters
- Organized Sports Help Enhance Motor Skills In Children With Autism
- Teal Health, UC Davis team up to expand HPV screening access
- D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
- Roche defends 6B franc Vabysmo peak sales target despite another quarterly miss
- BeOne jumps aboard onshoring train with $300M to add small molecule production in US
- People Living Longer, But Spending More Years With Illness And Disability
- Exercise Underwhelms As A Hip Arthritis Treatment, Review Concludes
- Tongue Pacemaker Might Improve Sleep Apnea Patients' Health
- Poll: Costs Are Top Health Care Issue For Midterm Voters, But Fraud Tops GOP List
- Listen to the Latest ‘KFF Health News Minute’
- A Death Revives Concerns About Police Brutality Six Years After National Reckoning
- Public Health Improvements Stall Amid Trump’s DEI Crackdown
- FDA rebukes 2 Indian API plants over data controls, sanitation issues
- Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
- J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial
- ARS Pharma drafts NFL legend Drew Brees in allergy awareness push
- Teladoc Health unveils new virtual care model for employers, health plans that ties payment to results
- Anterior, Stellarus enter strategic partnership to speed up AI-driven prior authorizations
- Amid ACA subsidy fallout, half of Community Health Systems' Q2 volume gains were uninsured patients
- CMS appeals court decision behind 2026 MA star ratings recalculations
- Boulder Care awarded NIH grant to provide SUD care in complex settings
- Prosper Medical banks $16M to scale AI-driven concierge care platform
- CMS proposed rule lays groundwork for more OBBBA provider tax cutbacks
- Measles Cases Set 35-Year US Record With Months To Go In 2026
- Taylor Farms Faces Cyclospora Outbreak, Recalls And Political Questions
- GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
- Cigna expands AI-powered care management programs for members
- Visana revamps well-woman visit to comprehensively address symptoms
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- What to Expect at PODD 2026
- Candid Health secures $120M series D as investment in AI-powered RCM ramps up
- GLP-1 Use Surges Among Young People With Obesity
- FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV
- Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data
- Trump floats countdown to 200% tariffs on generic drugs imported to US
- Summit Therapeutics updates ivonescimab survival data ahead of FDA decision date
- 1 In 4 Americans Stuck In Jobs For Health Insurance, Survey Finds
- How Does ADHD Affect Athletes' Concussion Risk?
- TV Does Indeed Rot Your Brain, Study Says
- Tick-Borne Meat Allergy: Many Carry Alpha-Gal Antibodies Without Symptoms
- Agencies In New York And Beyond Pass The Buck On Opioid Cash Oversight
- American Scientists See Prosecutions as Part of Federal Campaign Against Them
- Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records
- Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
- Remarks to the Small Business Capital Formation Advisory Committee
- Cannabis Drinks Sold Next To Soda Are Sending Kids To The ER, Doctors Say
- Coffee May Lower Your Heart Disease Risk, But How Much Is Safe?
- More Than Half Of US Adults Should Be Offered Statins, Study Says
- Gait Training Can Help Knee Arthritis
- The Best Surgery For Pelvic Organ Prolapse?
- Doctors 'Cringe' At Possibility Of Documenting Which Medicaid Enrollees Are Too Sick to Work
- Compounded Ozempic, Zepbound Still Widely Available Despite End Of Drug Shortages
- Leadership Vacuum: Agencies in New York and Beyond Pass the Buck on Opioid Cash Oversight
- FDA: Iceberg Lettuce Recall Stands After False Positive For Cyclospora
- Why Do So Many Women Miss The Signs Of Perimenopause?
- Virtual Therapy Sessions Improve Lives Of Kids With Lupus
- More Evidence Links Sleep Apnea To Dementia And Memory Loss
- Study Links GLP-1 Medications To Rare Vision Issue
- Gut Bacteria May Hold Key To Preventing Severe Peanut Allergies
- Trump's CDC Nominee Praises Vaccines, Without Vowing Independence From RFK Jr.
- CDC Warns Of Parasite Outbreak Tied To Taco Bell Lettuce In 5 States
- The Best Vegetables For Your Heart May Depend On Your Sex
- One Type Of ADHD Med May Affect Kids' Weight
- Poll: Many Older Americans Unaware Of 988 Suicide Help Line
- ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
- Statement on Regulation E-Delivery
- Paper Taper: Statement on Proposed Regulation E-Delivery
- Statement on Proposed Regulation E-Delivery
- Remarks before the American-Hellenic Chamber of Commerce
- Remarks at the Society for Corporate Governance Conference
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- Statement on the 2026 Regulatory Agenda
- Applying Agentic AI to Healthcare Delivery: The Key to True Transformation
- Applying Agentic AI to Healthcare Delivery: The Key to True Transformation
Michigan healthcare freedom community forum
Not exactly over-the-counter, actually pharmacist prescribed birth control pills:
Over-the-counter birth control hitting shelves, thanks to Michigan firm
- The FDA decided last year that a longtime birth control pill was safe enough to gain over-the-counter status.
- The drug, Opill, is the product of a Grand Rapids-based company which has headquarters in Ireland, too.
- The pill began shipping Monday at a cost of $20 a month, or $50 for a three-month supply.
By Robin Erb - March 4, 2024
The first over-the-counter daily birth control pill began shipping to pharmacies Monday, dramatically boosting convenience and access among oral contraceptives, especially for low-income women, those living in rural areas and those without easy access to transportation or child care.
On Monday, Opill — which is offered in a 28-day blister pack and is 98% effective against unplanned pregnancies when taken as directed — became available for the first time nationally.
It is the product of drugmaker Perrigo, which is based both in Grand Rapids and Ireland.The drug is being manufactured in Ireland, and its active ingredient, norgestrel, is being manufactured in Germany.
After months of anticipation by medical groups and consumer groups, the company announced the first, long-awaited shipments Monday morning.
“It’s revolutionary in terms of having women take control of their reproductive choices,” said Dr. Ann Gillett-Elrington, a staff physician and board-certified obstetrician at Western Wayne Family Health Centers.
The suggested retail price will be $20 for a one-month supply, $50 for a three-month supply and $90 for a six-month supply.
The relatively low cost is good news, especially for the uninsured or without regular medical care, she said.
“Appointments — sometimes they're far in between. People can get pregnant in the interval,” she said. “They also have to take time off from work (for an appointment) and they might have to make child arrangements.”
Given the cost of those things or an unplanned pregnancy, the pill “is very cost-effective,” she said.
The pill will be available at major retail pharmacies, including Walgreens and CVS, and through Amazon, said Perrigo’s chief commercial officer, Sara Young, who called the pill “groundbreaking.”
The French drugmaker HRA Pharma had begun seeking FDA approval for its over-the-counter product when Perrigo purchased the company in a sale completed in 2022.
Opill will also be sold online directly to consumers from opill.com on March 18, she said.
Long awaited
The U.S. Food and Drug Administration switched Opill, a progestin-only tablet, to an over-the-counter drug in July. Because it doesn’t contain the hormone estrogen, it may have few side effects. Most common side effects are irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA’s July announcement.
The drug had originally been approved in 1973. In making its decision last year, the FDA made it clear that the pill was safe and effective enough that Americans could decide on their own — with consulting with a doctor — whether Opill is appropriate for them.
That’s “obviously a very important step forward regarding convenience and access,” said Dr. Mark Fendrick, an internal medicine doctor and director of the Center for Value-Based Insurance Design at the University of Michigan.
About 26 million Americans are uninsured, according to the U.S. Census, making it difficult or too expensive to get regular medical care, he said.
Family planning, including options for oral contraception, is “a very effective, equitable and important public health and population health measure,” he said, so Opill is a “great step forward for access.”
Moreover, limitations or bans on abortion in some states make pregnancy prevention even more critical.
For its part, Right to Life of Michigan, aligning with national leaders of Right to Life, takes no position on products that prevent an egg’s fertilization, legislative director Genevieve Marnon, told Bridge Michigan, Monday.
Still unknown is whether insurers, including the state’s Medicaid program, will cover the costs of the pill.
The pill likely will show up at local pharmacies later this month, said Farah Jalloul, state emergency preparedness coordinator at the Michigan Pharmacists Association. And pharmacies can decide whether they will carry the pill, she noted, though she added that most undoubtedly will do so.
When it hits the shelves, it will be available to consumers of any age — a concern for some who worry about adolescents or some adults who might be unable to follow directions or understand contraindications.
Among those who should not take Opill are women with a history of breast cancer. People who have any other form of cancer should consult their doctor before taking Opill. And Opill is not for use as emergency contraception nor does it prevent sexually transmitted infections.
Ideally, said Gillett-Elrington at Western Wayne Family Health Centers, a young person or an adult with questions will talk with a trusted medical professional before taking Opill, though there are no guarantees, she acknowledged.
The drug works mainly by thickening a person’s cervical mucus, thereby blocking sperm from reaching the egg. Opill also may prevent an egg from implanting or altogether block its release from the ovaries. But a pill from the 28-day blister pack must be taken every day.
More than one in three women using oral contraceptives (36%) had missed taking doses because they were unable to get their next supply, according to a 2022 KFF Women’s Health Survey.Medical groups, including the American Medical Association, had urged the FDA to approve over-the-counter daily contraception. And the American College of Obstetricians and Gynecologists Monday lauded the release, and released guidelines for clinicians.
ACOG President Dr. Verda J. Hicks, called Opill a safe drug for patients of all ages, including adolescents.
It’s a “key component of reproductive health care” in a country where there are “increasing healthcare deserts … where people do not have access to gynecologic care,” she said in a prepared statement.
Despite some initial concerns that consumers might not be able to understand how to take the pills or why some patients should not take the pills, ACOG doctors “trust our patients to determine if this OTC method is best for them.”
Perrigo executed a corporate tax inversion to Ireland eleven years ago to avoid U.S. corporate taxes. It was 'acquired' by Irish-based Elan Corporation for $ 8.6 billion. The combined company is now known as Perrigo Company plc.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.





















